机译:新的基于证据的适应性临床试验方法,可将预测生物标志物最佳地整合到肿瘤学临床开发计划中
Oncology Clinical Research, Daiichi Sankyo Pharmaceutical Development, Edison, New Jersey 08837, USA;
Center for Evolution and Cancer, Helen Diller Family Cancer Center, University of California at San Francisco, San Francisco, California 94115, USA;
Biostatistics and Research Decision Sciences, Merck & Co., North Wales, Pennsylvania 19454, USA;